Compare Citius Pharmaceuticals Inc (CTXR) vs Phillips 66 (PSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Phillips 66 — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Phillips 66 trades at $279.69 (market cap $112.36B). The key difference: Phillips 66 is far larger — about 8249.6× Citius Pharmaceuticals Inc's market cap, and Phillips 66 pays a 1.8% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Phillips 66 for 62 Days on average.
| CTXR | PSX | |
|---|---|---|
Market Cap | $13.62M | $112.36B |
Volume | 132,438 | 2,374,751 |
Sector | Health | Energy |
52-Week High | $1.82 | $281.60 |
52-Week Low | $0.48 | $126.76 |
Typical Hold Time | 16 Days | 62 Days |
Enterprise Value | $3.79M | $128.83B |
Dividend Yield | — | 1.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Phillips 66 (PSX) trades at $271.62, up 0.68% with a bullish technical outlook near its 52-week high. The stock shows strong profitability with 24.02% ROE and 4.66% net margin, supported by three consecutive earnings beats. Recent news highlights structural refining advantages and AI implementation for operational efficiency. Current valuation metrics include a P/E of 16.07 and P/S of 0.75, suggesting reasonable pricing relative to peers.
PSX presents a compelling investment case with analyst consensus at Buy (54% rating) and $279 price target, though revenue declines from 2022-2025 pose concerns. Key risks include diesel export policy uncertainty and refining margin volatility. The company's debt reduction progress and projected 2026 earnings recovery to $7.1B support upside potential if operational execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
